PARP Inhibition. DNA Repair Machinery
|
|
- Briana Summers
- 5 years ago
- Views:
Transcription
1 UNIVERSITY UNIVERSTY OF TORINO OLOGICAL SCIENCES PARP Inhibition Silvia Novello, MD PhD University of Torino Italy Thoracic Oncology Unit OLOGICAL SCIENCES DNA Repair Machinery An intact DNA repair machinery is critical to withstand damage to cellular DNA DNA are constantly subject to DNA damage Multiple DNA repair mechanisms have been described Base excision repair Nucleotide excision repair Mismatch repair Recombination repair Translesion synthesis Beljanski et al, Mol Pharmacol 2004
2 DNA Repair Machinery and Cancer A number of tumors are characterized by the loss of functionality in one or several DNA repair pathways Some breast and ovarian cancers: BRCA1 or BRCA2 repression/mutation, which are essential genes in the homologous recombination repair pathway Colon cancer: methylated promoter/loss of hmlh1 or MSH2 expression, essential proteins in the mismatch repair pathway Gliomas: methylated promoter/loss of MGMT expression Lung cancer: loss of ERCC1 expression Matteo Giaj Levra, Ken André Olaussen, Silvia Novello, Jean Charles Soria Current Pharmaceutical Design 2012 Submitted Paper DNA Repair Pathway Pathways Lesions Biomarkers Modified from Ding et al. Trends in Pharm. Sciences, 2006
3 At least 17 members of PARP family have been described PARP-1 localizes to the site of DNA damage and recruits proteins that 18 mediate members repair of PARP super-family identified to date PARP-1 Double abundant knockout nuclear of PARP enzyme 1 & activated 2 results by and binds with in embryonal high affinity lethality to DNA single to mice and double strand breaks via N zinc fingers Dantzer et al, Biochemistry 2000; McCabe et al, Cancer Res 2006 PARP-1 essential for the repair of damaged bases and single strand breaks via the Base Excision repair pathway PARP-1 Role of PARP 1 in BER/SSBR A - DNA binding domain ZF D - Automodification domain ZF NLS C BRCT B - Nuclear localisation signal E F - Catalytic domain C XRCC1 Courtesy of JC Soria OLOGICAL SCIENCES Consequence of PARP Inhibition The affinity of PARP1 for platinum modified DNA in vitro has been established using modified cisplatin analogues to synthesize 25 bp DNA duplexes carrying platinum intrastrand crosslinks 1 PARP could facilitate the dissociation of nuclear proteins from platinum modified DNA that in turn could facilitate recruitment of DNA repair proteins 2 PARP inhibitors also radiosensitize cancer cells 3 1 Guggenheim ER et al, Chembiochem 2009; 2 Nguewa PA Med Chem 2006; 3 Calabrese CR et al J Natl Cancer Inst 2004
4 Powell C et al, Cancer Treat Review 2010 OLOGICAL SCIENCES Veliparib + XRT in H460 Tumors Albert et al, Clin Cancer Res, 2007.
5 PARP 1 Inhibitors in Development Company Product (Route) Single/Combination Development BiPar Sciences (Sanofi Aventis) BS 201/Iniparib (IV) Combination with: RT, GemCarbo, CisGem, temozolomide Phase III Astra Zeneca AZD2281/Oliparib Single/Combination Phase III (oral) Pfizer AG (IV) Single/Combination Phase II Abbott ABT 888/Veliparib Single/Combination Phase I/II (oral) Cephalon CEP 9722 (IV) Combination with temozolomide Phase I MGI Pharma GPI (oral) Combination with Phase I temozolomide Merck MK 4827 (oral) Single Phase I Inotek/Genentech INO 1001 (IV) Single/Combination with temozolomide Phase I Lung Trials Ph II closed, Ph III ongoing Some Designs None None None None None None OLOGICAL SCIENCES Olaparib Phase I Trial Expansion phase: enriched for BRCA 1 or 2 mutation carriers (N=22) Daily oral dosing 19 evaluable patients with BRCA mutation 12 patients (63%) had meaningful clinical benefit 9 patients had an objective partial response Ovarian, breast and prostate cancers Fong PC et al, N Engl J Med, 2009
6 Olaparib Phase I Trial Fong PC et al, N Engl J Med, 2009 OLOGICAL SCIENCES UNIVERSITY UNIVERSTY OF TORINO Olaparib Phase I Trial Most toxicities were Grade 1 2 ( 95%) Most common toxicities were: nausea 28%, vomiting 18%, dysgeusia 13%, anorexia 12% fatigue 28% Grade 3 4 toxicities were rare: myelosuppression ( 5%) nausea and vomiting (2 3%) CNS: dizziness or mood changes (2 3%) No increase in the frequency of grade of adverse events was observed comparing known BRCA1 or BRCA2 mutation carriers with non carriers Fong PC et al. NEJM 2009
7 Olaparib as Monotherapy: Phase II Trials OLOGICAL SCIENCES Ovarian Cancer N=57 patients with BRCA 1/2 mutation ORR: 38% 400mg bd; 13% 100mg bd Grade 3,4 toxicities in 51% 100mg bd and 58% 400mg bd (nausea, fatigue) Audeh MW et al. The Lancet 2010 Refractory Breast Cancer N=54 patients with BRCA 1/2 mutation ORR: 41% 400mg bd; 22% 100mg bd PFS: 5.7 mo 400mg bd; 3.8mo 100mg Good Tolerability (grade 3 tox in 5 pts as nausea, fatigue, anemia) Tutt A et al. The Lancet 2010 OLOGICAL SCIENCES Olaparib as Monotherapy: Phase II Trials ICEBERG 3 phase II randomized Metastatic Ovarian Cancer Carrying BRCAmutation Audeh MW et al. The Lancet 2010 Olaparib (400 or 200 mg) pegylated liposomial Doxorubicin Refractory Breast Cancer N=54 patients with BRCA 1/2 mutation ORR: 41% 400mg bd; 22% 100mg bd PFS: 5.7 mo 400mg bd; 3.8 mo 100mg Good Tolerability (grade 3 tox in 5 pts as nausea, fatigue, anemia) Tutt A et al. The Lancet 2010
8 Platinum + PARP Inhibition Platinum compounds exert cellular cytotoxicity Enhanced DNA repair capacity is a known mechanism for resistance to platinum Combination ofparp inhibitor with platinum has demonstrated pre clinical synergy Miknyoczki SJ et al, MolCancerTher2003; Nguewa PA et al Med Chem OLOGICAL SCIENCES Veliparib + Platinum Cisplatin Carboplatin Donawho et al, Clin Cancer Res, 2007
9 BSI 201 and Breast Cancer Randomized phase II study Primary objective Clinical benefit rate Metastatic Breast cancer Triple negative disease N=123 patients Carboplatin AUC2 Gemcitabine 1000mg/mq days 1,8 every 21 days BSI 201 5,6 mg/kg i.v. biweekly on days 1, 4, 8 and 11 Carboplatin AUC2 Gemcitabine 1000mg/mq days 1,8 every 21 days ASCO 2009 O Shaughnessy J et al., abstract 3; O Shaughnessy J et al., Cancer Res 2009, abst 3122; NEJM 2011 Results: RR 52% vs. 32% Clinical benefit 56% vs. 34% PFS 5.9 vs 3.6 mo (HR 0.59; 95% CI, 039to ; P = 001) 0.01) OS 12.3 mo vs 7.7 mo (HR 0.57; 95% CI, 0.36 to 0.90; P = 0.01) OLOGICAL SCIENCES O Shaughnessy J et al., NEJM 2011 BSI 201 and Breast Cancer
10 O Shaughnessy J et al., NEJM 2011 BSI 201 and Breast Cancer OLOGICAL SCIENCES PARP Inhibitors in NSCLC: Potential Roles Usein combination with platinum based regimens Platinum compounds continue to be the cornerstone of treatment of both SCLC and NSCLC Use in combination with radiotherapy Monotherapy is unlikely to be useful since BRCA mutation are not noted frequently in lung cancer
11 Results of a Phase2 Study of Gemcitabine/Cisplatin/iniparib (GCI) Versus Gemcitabine/Cisplatin (GC) in Patients with Advanced NSCLC Novello S, 1 Felip E, 2 Barlesi F, 3 Mazieres J, 4 Zalcman G, 5 von Pawel J, 6 Reck M, 7 Cappuzzo F, 8 Ferry D 9 and Soria JC 10 1 University of Torino San Luigi Hospital Orbassano, Torino/ITALY, 2 Vall d'hebron Institute of Oncology, Barcelona/SPAIN, 3 Hôpital Nord, Marseille/FRANCE, 4 CHU Toulouse Hopital Larrey, Toulouse/FRANCE, 5 Caen University Hospital/FRANCE, 6 Asklepios Fachkliniken München-Gauting, Gauting/GERMANY, 7 Hospital Grosshansdorf, Grosshansdorf/GERMANY, 8 Istituto Toscano Tumori-Ospedale Civile, Livorno/ITALY, 9 New Cross Hospital, Wolverhampton/UNITED KINGDOM, 10 Institut Gustave Roussy, Villejuif/FRANCE OLOGICAL SCIENCES Background Backbone upfront therapy for inoperable non small cell lung cancer (NSCLC) is platinum based chemotherapy Gemcitabine/cisplatin (GC) is a widely used regimen In a Phase 3 trial (N=863) in patients with NSCLC treated with GC 1 Overall survival (OS) was10.3 months (1 year survival rate, 41.9%) Progression free survival (PFS) was 5.1 months Objective response rate (ORR) was 28.2% Rationale for iniparib (BSI 201) in NSCLC A novel, investigational anticancer agent Preclinical studies with iniparib have shown: 2 5 Induction of g H2AX marker of DNA damage Does not inhibit PARP1/2 at physiologic drug concentrations Potentiation of cell cycle arrest induced by DNA damaging agents No potentiation of chemotherapy related toxicities observed when combined with gemcitabine/carboplatin 6 1. Scagliotti GV, et al. J Clin Oncol 2008;26: ; 2. Ossovskaya V, et al. SABCS 2010, Abstr P ; 3. Ossovskaya V, et al. AACR 2009, Abstr 5552; 4. Ossovskaya V, et al. AACR 2011, Abstr LB-401; 5. Ji J, et al. AACR 2011, Abstr 4527; 6. O Shaughnessy J, et al. N Engl J Med 2011; 364:
12 O Study Design Multi-center, multi-national, randomized open-label Phase 2 (N=119) Study Population Untreated stage IV NSCLC ECOG PS 0 1 Measurable disease Randomization stratified by: - squamous vs. non-squamous - ever smoker vs. never Study Objectives* R 2:1 Gem/Cis + Iniparib (N=80) Gemcitabine 1250 mg/m 2 iv d 1, 8 Cisplatin 75 mg/m 2 iv d 1 Iniparib 5.6 mg/kg iv d 1, 4, 8, day cycles Gem/Cis (N=39) Gemcitabine 1250 mg/m 2 iv d 1, 8 Cisplatin 75 mg/m 2 iv d 1 21-day cycles Primary endpoint: ORR (RECIST 1.1; investigator assessed) Secondary endpoints: Safety, PFS, OS Exploratory molecular substudy: Biomarker analysis; PD ECOG PS, Eastern Cooperative Oncology Group performance status; Gem/Cis, gemcitabine/cisplatin; ORR, overall response rate; OS, overall survival; PD, pharmacodynamics; PFS, progression-free survival. *Efficacy populations intent-to-treat (ITT) all randomized patients. 6 Cycles max with no maintenance phase NCT OLOGICAL SCIENCES GC (N=39) GCI (N=80*) All Patients (N=119) Age, years median (range) 58 (29 73) 59 (37 73) 59 (29 73) ECOG PS, % Patient Baseline Characteristics 0/1 49/51 61/39 57/43 Male gender, % Smoking status, % Smoker/never smoker 90/10 89/11 89/11 Stage at diagnosis, % Stage I/III/IV 3/8/90 1/3/96 2/4/94 Histology, n (%) Adenocarcinoma 28 (72) 57 (71) 85 (71) Squamous cell carcinoma 5 (13) 10 (13) 15 (13) Large cell carcinoma 5 (13) 6 (8) 11 (9) Other 1 (3) 7 (9) 8 (7) *2 patients on the GCI arm were randomized but not treated.
13 Summary of Drug Exposure (Safety Population) Relative dose intensity, median (%) GC (N=39) GCI (N=78) Gemcitabine (G) Cisplatin (C) Iniparib (I) 91 Cycles completed, n (%) (33) 19 (24) (23) 20 (26) (44) 39 (50) OLOGICAL SCIENCES Response Rates (ITT Population) Best response, n (%)* GC (N=39) GCI (N=80) Complete response (CR) 0 (0) 1 (1) Partial response (PR) 10 (26) 15 (19) Stable disease (SD) 17 (44) 44 (55) Progressive disease (PD) 8 (21) 11 (14) Not evaluable (NE) 4 (10) 9 (11) ORR (CR + PR) 26% 20% (95% CI) (13 42) (13 32) *According to RECIST 1.1: Confirmation of response after 4 weeks required; SD required 35 days after first dose. No differences in response by subgroups were seen (data not shown).
14 Max. change from baseline (% %) Best Target Lesion Response* CR PR SD/PD/NE GC Order of subjects *In patients with post-baseline tumor assessments. Max. change from baseline (% %) GCI Order of subjects OLOGICAL SCIENCES UNIVERSITY UNIVERSTY OF TORINO l Probability of surviva Progression Free Survival (ITT Population) 100 GC GCI (N=39) (N=80) 90 Median PFS, months (95% CI) (2.8, 5.6) (4.6, 6.6) HR (95% CI) 0.89 (0.56, 1.41) 70 p-value Time (Months) Number at Risk G/C G/C/I Median follow up time for PFS was 4.1 months
15 OLOGICAL SCIENCES UNIVERSITY UNIVERSTY OF TORINO Probability of surviva al Preliminary Overall Survival (ITT Population) 100 GC GCI (N=39) (N=80) 90 Median OS, months (95% CI) (5.5, NE) (8.9, NE) HR (95% CI) 0.75 (0.44, 1.27) 70 p-value Time (Months) Number at Risk G/C G/C/I At the time of the analysis 56% of patients in GC and 48% in GCI were dead Median follow up time for OS was 8.4 months OLOGICAL SCIENCES Safety Deaths within 30 days for GC vs. GCI arms Due to adverse events (AEs): 2 (5%) vs. 3 (4%) Due to disease progression: 1 (3%) vs. 2 (3%) Summary of treatment emergent AEs (TEAEs): *N=39 and N=78 are the safety populations for the GC and GCI arms, respectively. GC (N=39)* n (%) GCI (N=78)* n (%) Patients with any Grade 3/4 TEAE 32 (82) 66 (85) Patients with any related Grade 3/4 TEAE 25 (64) 51 (65) Patients with any treatment-emergent SAE 17 (44) 40 (51)
16 Treatment Emergent Adverse Events* GC (N=39) GCI (N=78) Adverse Event All Grades Grade 3/4 All Grades Grade 3/4 n (%) n (%) n (%) n (%) Neutropenia 18 (46) 15 (39) 34 (44) 28 (36) Febrile neutropenia 3 (8) 3 (8) 0 0 Thrombocytopenia 10 (26) 9 (23) 19 (24) 17 (22) Anemia 11 (28) 4 (10) 23 (30) 12 (15) Nausea 34 (87) 1 (3) 49 (63) 11 (14) Asthenia 31 (80) 11 (28) 52 (67) 6 (8) Decreased appetite 16 (41) 4 (10) 33 (42) 8 (10) Vomiting 16 (41) 3(8) 29 (37) 6(8) Hypertension 9 (23) 3 (8) 12 (15) 6 (8) Hyponatremia 6 (15) 6 (15) 5 (6) 5 (6) Fatigue 4 (10) 2 (5) 11 (14) 4 (5) Pulmonary embolism 3 (8) 3 (8) 5 (6) 5 (6) Hypokalemia 2 (5) 2 (5) 4 (5) 4 (5) * 5% Grade 3/4 in GCI arm except for febrile neutropenia. OLOGICAL SCIENCES Conclusions for Phase II Trial Addition of iniparib to GC did not improve ORR in this population of patients with NSCLC Caution should be used when interpreting the 1.4-month increase in median PFS and preliminary 2.7 months in median OS seen in the GCI vs. GC arm due to baseline imbalances in PS and gender distribution PFS and OS in the control arm are below published efficacy for gemcitabine and cisplatin in NSCLC The toxicity profile of GCI was similar to that observed with GC alone Biomarker studies are ongoing to potentially define a subgroup of patients that may benefit from iniparib treatment
17 O Phase 3 Squamous Cell Lung Cancer Study International, Open-label Patient Population: Advanced SCC Endpoints: Primary: OS Secondary: PFS, TTP, ORR, safety/tolerability, QoL Doses: Gemcitabine 1000 mg/m 2 D 1 & 8 + Carboplatin AUC 5 D1 q3wk; Iniparib 5.6 mg/kg IV D 1, 4, 8 & 11 q3wk N= 825 (planned) R 1:1 Gemcitabine + Carboplatin (G/C) Patients restaged by CT scans (per RECIST 1.1 version) q 2 cycles (6 wks) Patients may remain on study after 6 cycles if there is no evidence of PD or the presence of DLTs G/C + iniparib First Patient Enrolled: March 5, OLOGICAL SCIENCES Conclusions PARP inhibition is one of the novel strategies for the treatment of cancer Early phase clinical trials have demonstrated good tolerability of PARP inhibitors and promising efficacy Studies with PARP inhibitors are underway in NSCLC
HDAC Inhibitors and PARP inhibitors. Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine
HDAC Inhibitors and PARP inhibitors Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine Histone Acetylation HAT Ac Ac Ac Ac HDAC Ac Ac Ac Ac mrna DACs
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationPathways Underlying Aggressive Breast Cancers
Origin of Breast Cancer Subtypes Pathways Underlying Aggressive Breast Cancers HER2 and ER can be expressed in any subtype. Triple Negative -- a mixture of subtypes Joyce O Shaughnessy, MD Baylor Sammons
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationTrabectedina + PLD nel trattamento del carcinoma ovarico. Nicoletta Colombo Universita Milano Bicocca Istituto Europeo Oncologia Milano
Trabectedina + PLD nel trattamento del carcinoma ovarico Nicoletta Colombo Universita Milano Bicocca Istituto Europeo Oncologia Milano The old definition of Recurrent Ovarian Cancer P R I M A R Y T H E
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationTargeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer
Targeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer Andrew Tutt, MB ChB, PhD Consultant Oncologist/Director Breakthrough Breast Cancer Research Unit King s Health Partners Academic Health
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationCombining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer
Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer Dr Martin Forster MD PhD Clinical Senior Lecturer in Experimental Cancer Medicine Consultant in Medical Oncology UCL
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationUpdate on Breast Cancer
Update on Breast Cancer William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center Feinberg School of Medicine Northwestern University Overview PARP Inhibitors Neoadjuvant
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationTreatment of Recurrent Ovarian Cancer
Treatment of Recurrent Ovarian Cancer Mihaela Cristea, MD Associate Professor Medical Oncology, City of Hope November 11, 2016 No disclosures Financial Disclosure Epithelial Ovarian Cancer Subtypes and
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationPost-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationALK positive Lung Cancer. Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan
ALK positive Lung Cancer Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan Objectives What is ALK translocation? What drugs are used in what sequence? How many times
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationOpzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationNuevas estrategias de tratamiento en tumores con mutaciones de BRCA
Nuevas estrategias de tratamiento en tumores con mutaciones de BRCA Emilio Alba UGCI Oncología Hospital Universitario Regional y Virgen de la Victoria Facultad de Medicina. Málaga IBIMA ÍNDICE DE LA PRESENTACIÓN
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationVEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More information